for Health Care Providers
Drug Interactions between Hepatitis C Direct-Acting Antivirals and HIV Antiretrovirals
The table below indicates the clinically significant published drug interactions between hepatitis C direct-acting antivirals (DAA) and HIV antiretrovirals.
|DAA||Mechanism||FDA status||Genotype||Barrier to resistance||Potential ARV interactions|
|Telaprevir||NS3/4A protease inhibitor||Approved 2011||1||Low|
Contraindicated with protease inhibitors and NNRTIs except atazanavir/ritonavir and efavirenz
Requires increased dosage of telaprevir (1125mg Q8h) when administered with efavirenz
|Boceprevir||NS3/4A protease inhibitor||Approved 2011||1||Low|
Contraindicated with boosted and unboosted protease inhibitors and efavirenz
No clinically significant interactions with raltegravir
|Simeprevir||NS3/4A protease inhibitor||Approved 2013||1, 2, 4, 5, 6||Low|
Concentrations decreased in presence of efavirenz
Concentrations increased in presence of darunavir/ritonavir, ritonavir (100mg bid) and cobicistat-containing products. It is not recommended to co-administer simeprevir with any HIV protease inhibitor (with or without ritonavir).
No clinically significant interactions with raltegravir, rilpivirine, tenofovir.
|Sofosbuvir||NS5B RNA polymerase inhibitor||Approved 2013||1-6||High|
Concentrations decreased in presence of tipranavir/ritonavir; coadministration not recommended.
No clinically significant interactions with darunavir/ritonavir, efavirenz, emtricitabine, raltegravir, rilpivirine, or tenofovir.